Compositions and methods for immune-mediated cancer therapy
AssigneeTeclison Limited
InventorRuey-min Lee
Life of this patent
Estimating the term…
Abstract
Disclosed herein are methods and compositions for enhancing an immune response to a solid tumor in a subject. In some embodiments, a method comprises: (a) administering to the subject a hypoxia-activated bioreductive agent (HABA); (b) inducing hypoxia by (i) administering a hypoxia-inducing agent to the subject or (ii) embolizing one or more blood vessels supplying the solid tumor; and (c) administering an immune checkpoint inhibitor prior to, simultaneously with, or subsequent to step (b) in an amount effective to enhance an immune response to the solid tumor, as compared to an immune response in the absence of the immune checkpoint inhibitor. Kits for use in the disclosed methods are also provided.
Claims22
A method of treating a cancer in a subject having a solid liver tumor, the method comprising:
- (a) administering tirapazamine to the subject;
- (b) inducing trans-arterial embolization of one or more blood vessels supplying the liver of the subject;
- and
- (c) administering nivolumab or pembrolizumab to the subject prior to, simultaneously with, or subsequent to inducing trans-arterial embolization of the one or more blood vessels supplying the liver of the subject.
A method of treating a cancer in a subject having a solid liver tumor, the method comprising:
- (a) administering tirapazamine to the subject;
- (b) inducing trans-arterial embolization of one or more blood vessels supplying the liver of the subject;
- and
- (c) administering nivolumab or pembrolizumab to the subject subsequent to inducing trans-arterial embolization of the one or more blood vessels supplying the liver of the subject.
A method of treating a cancer in a subject having a solid liver tumor, the method comprising:
- (a) administering tirapazamine to the subject;
- (b) inducing trans-arterial embolization of one or more blood vessels supplying the liver of the subject;
- and
- (c) administering nivolumab or pembrolizumab to the subject prior to and subsequent to inducing trans-arterial embolization of the one or more blood vessels supplying the liver of the subject.
Dependencies are inferred from the claim text.